BiotechTube
Liferna Biotech

Liferna Biotech

Cambridge, United States· Est.
liferna-biotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Liferna Biotech is a private, pre-clinical-stage biotech focused on addressing high-unmet-need autoimmune and fibrotic diseases through RNA therapeutics. The company's strategy centers on a proprietary platform technology designed for targeted drug delivery to minimize off-target effects and enhance therapeutic efficacy. With a seasoned founding team and a clear initial focus on systemic sclerosis, Liferna aims to accelerate novel treatments from the clinic to the market. The company is currently pre-revenue and in the platform validation and early pipeline development phase.

Autoimmune DiseasesFibrotic Diseases

Technology Platform

Proprietary platform for targeted delivery of RNA-based therapeutics, designed to minimize off-target effects and enhance efficacy in specific cells and tissues.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The large and growing unmet need in autoimmune and fibrotic diseases, particularly in rare conditions like systemic sclerosis with no cure, presents a significant market opportunity.
Success with its lead program could validate the proprietary platform, enabling rapid expansion into other fibrotic and autoimmune indications, creating a broad pipeline.
The company's focus on targeted delivery could provide a key differentiation in safety and efficacy over broader-acting systemic therapies.

Risk Factors

High scientific risk that the novel RNA delivery platform may not prove effective or safe in human trials.
Substantial financing risk, as the pre-revenue company will require large capital infusions to advance through costly clinical development.
Intense competition from larger biopharma firms and other biotechs pursuing diverse therapeutic approaches for fibrosis and autoimmune diseases.

Competitive Landscape

Liferna operates in the highly competitive RNA therapeutics and fibrosis spaces, competing against large-cap biotechs (e.g., Alnylam, Ionis, Biogen) and pharma companies with advanced platforms. In systemic sclerosis, competitors include companies developing biologics, small molecules, and cell therapies targeting immune and fibrotic pathways. Liferna's key differentiator is its focus on targeted RNA delivery specifically for fibrotic diseases, aiming for precision where others may have broader mechanisms.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →